Benefits of Autoantibody Enrichment in Early Rheumatoid Arthritis: Analysis of Efficacy Outcomes in Four Pooled Abatacept Trials.

When regressing SPEAR status on all four SPEAR criteria, all four criteria were highly significant ( p < 0.001) with odds ratios of 3.33 (CI [2.63, 4.55]) for DAS28 (CRP) ≥ 3.2, 2.33 (2.17, 2.5) for ACPA + , 2.17 (2.04, 2.38) for RF + , and 1.19 (1.16, 1.22) for disease duration < 1 year, where odds ratios > 1 indicate higher odds for SPEAR (vs. non-SPEAR).

also in 132,142 other papers